Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2017, provides an overview of the Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape.
Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord Symptoms include tremors, speech difficulties, muscle weakness, muscle wastage, muscle cramps and spasms and gynaecomastia. Treatment includes balanced diet and medications to reduce muscle cramps and tremors.
Report Highlights Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively.
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Sleep Market Report
The sleep market by revenue is expected to grow at a CAGR of 6.11% during the period 2020–2026.
Several research studies and government programs help improve awareness explaining the importance of sleep in many countries.
Global Emerging Mental Health Devices and Platforms Market to Reach $18,717.5 Million by 2030
Market Report Coverage - Emerging Mental Health Devices and Platforms
• Product Type (Platforms and Devices)
• Application (Stress, Anxiety, Depression, Bipolar Disorder,...
The World Health Organization (WHO) made the following statement many years ago, “There is no health without mental health”.Today, as the COVID-19 pandemic ravages the world, another public health crisis is looming over our health systems—that of deteriorating mental health.
Mass unemployment, salary reductions, depleting financial...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Central Nervous System Disorders Therapeutics Market 2021-2025 The analyst has been monitoring the central nervous system disorders therapeutics market and it is poised to grow by $ 24.35 bn during 2021-2025, progressing at a CAGR of 4.44% during the forecast period. Our report on the central nervous system disorders...
The global behavioral health software market is expected to reach USD 4.9 billion by 2026 from USD 2.0 billion in 2021, at a CAGR of 19.6% during the forecast period. The major factors driving the growth of behavioral health software are the increasing adoption of behavioral health software, availability of government funding, government initiatives...
As people learn to embrace uncertainty, the top trends outlined at the beginning of 2021 will bring about significant changes in the way societies work and live. Changes in user behavior patterns will trigger major growth opportunities influenced by changes in consumption and business models.Emerging advancements in technologies, such as AI...
175 pages •
By The Business Research Company
• May 2021
Major players in the individual and family services market are CARE International, Children’s Aid and Family Services Inc., Eastwick Family Services, Executive Healthcare Services (EHS), Feeding America, Goldfields Individual and Family Support Association (GIFSA), Kairos Family Services, North East Independent Living Services, StepStone Family...
This IDC Perspective discusses drastic changes in the world of work during 2020 and the challenges organizations are facing as a result. Many of these challenges are related to unpreparedness to face new realities due to the work culture; technological solutions that address such challenges were perhaps not as widely adopted or well established...
205 pages •
By Global Industry Analysts
• Apr 2021
- Global Behavioral/Mental Health Software Market to Reach $3.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Behavioral/Mental Health Software estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at aCAGR of 14.3% over the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.